Cerecor is a biopharmaceutical company. The company is building a pipeline of therapies in neurology, pediatric healthcare, and orphan rare diseases. The company's neurology pipeline is led by CERC-301, which is in a Phase I safety study for Neurogenic Orthostatic Hypotension. The company is also developing two other neurological clinical and preclinical stage compounds. The company's pediatric orphan rare disease pipeline is led by CERC-801, CERC-802 and CERC-803. All three of these compounds are preclinical therapies for inherited metabolic disorders known as Congenital Disorders of Glycosylation by means of substrate replacement therapy.
  • TickerCERC
  • ISINUS15671L1098
  • ExchangeNASDAQ Stock Market
  • SectorPharmaceuticals & Biotechnology
  • CountryUnited States
Jonathan Moreland

InsiderInsights Daily Ratings Report: January 12, 2021

InsiderInsights Ratings of Companies with Open-Market Form 4 Purchases; Sales Filed at the SEC on the date above. We separate the real investment intelligence from the noise. Saving you time, and improving your research process

ResearchPool Subscriptions

Get the most out of your insights

Get in touch